Treatment outcomes in patients with seropositive versus seronegative rheumatoid arthritis in Phase III randomised clinical trials of tofacitinib
Objectives Tofacitinib is an oral JAK inhibitor for the treatment of rheumatoid arthritis (RA). We examined response to tofacitinib 5 or 10 mg two times a day in patients with seropositive vs seronegative RA.Methods Data were pooled from five Phase III studies of conventional synthetic disease-modif...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2019-06-01
|
| Series: | RMD Open |
| Online Access: | https://rmdopen.bmj.com/content/5/1/e000742.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|